Buckingham Palace in London, the Pentagon in Virginia and the Empire State Building in New York City have something in common, reveals a new study.
Animal feed that's easier to digest. Potatoes that don't go brown. And an improved industrial oil.
A recent investigation raises concerns over poor quality, lack of regulation and misrepresentation of animal studies for drug development.
An international collaboration, led by Melbourne researchers, has solved a longstanding malaria mystery.
Dr Michael Gantier, Research Group Head, Nucleic Acids and Innate Immunity at the Hudson Institute in Melbourne, reflects on the latest developments in the field of infection and immunity and his lab's current focus and future plans.
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017 held in Geneva, Switzerland.
Upstream Medical Technologies has developed a biomarker-based diagnostic test to rule out the risk of imminent heart attack for the significant number of people presenting at hospital with chest pain.
Australian researchers have developed a new risk scoring system for children with leukaemia based on missing DNA fragments or ‘microdeletions’.
Australian and Sri Lankan medical researchers have forged a new action plan to investigate the causes of a particular form of chronic kidney disease.
University of Leicester experts in association with the spin-off company MIP Diagnostics have developed polymeric materials with molecular recognition capabilities which hold the potential to outperform natural antibodies in various diagnostic applications.
Scientists have reconstructed a fully functional epidermis, covering approximately 80% of the total body surface area, for a seven-year-old patient with a genetic skin disease called Junctional Epidermolysis Bullosa (JEB).
A group of international researchers has developed a web tool, RefEx, that can easily search gene expression data available in public databases.
Research led by ANU has found that the proportion of 'staph' infections resistant to antibiotics has increased in Australia since 2000, with most cases now occurring in the community rather than in hospitals.
Melbourne researchers have produced a three-dimensional (3D) map of a molecular 'scaffold' called SgK223, known to play a critical role in the development and spread of aggressive breast, colon and pancreatic cancers.
Global healthcare company MSD and the University of Queensland's commercialisation company, UniQuest, have partnered to develop a platform for new immuno-oncology therapies.